Rheumatoid arthritis (RA), an autoimmune disorder characterized by inflammation of the synovial joints and surrounding tissues, affects 1.5 million adults in the United States. The past decade has seen a tremendous amount of change in the field of RA: in addition to advances in treatment such as targeted therapies, a number of initiatives have been developed to improve the management of RA and quality of care. These include the latest guidelines and recommendations developed by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), which support the identification of a therapeutic window and the desirability of tight disease control. As RA imposes a considerable burden on patients, their families, and society, therapeutic approaches call for early intervention with disease-modifying antirheumatic drugs (DMARDs), as either monotherapy or combination therapy, in order to avoid irreversible damage, long-term disability, and premature death. Numerous effective therapeutic options are now available, which facilitate individualization of treatment to optimize patient outcomes. This case exemplifies how modern treatment concepts and newer therapies apply to patients with early RA.
Ratings and Reviews
To review this course, please login.Login